par MEDESIS PHARMA (EPA:ALMDP)
Termination of the agreement between NICE and GREEN S.A. and Medesis Pharma
medesis PRESS RELEASE
Termination of the agreement between NICE and GREEN S.A. and Medesis Pharma
Montpellier, January 19, 2024 - 6.00 pm - MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary delivery technology, has signed a convertible bond financing agreement on March 30, 2023 to provide financing for the company.
A financing agreement involving the issue of Convertible Bonds was signed between MEDESIS PHARMA and NICE & GREEN S A. on March 30, 2023
NICE & GREEN S A. had contributed €1 million in April 2023, corresponding to the issue of two €500,000 bonds. No additional contributions were made afterwards.
Since the end of the financial year 2023, MEDESIS PHARMA no longer expected any cash contributions from NICE & GREEN S A. , which had informed the company that it no longer wished to participate in Convertible bonds issues.
The funding obtained by MEDESIS PHARMA since September 2023 has been provided exclusively by private individual shareholders.
The termination of the contract relieves the two parties of their obligations described in the contract.
 |  | ||
NICE & GREEN S A. has proposed that the sale and conversion process should continue until the total amount of the outstanding Convertible Bonds has been recovered by NICE & GREEN S A
MEDESIS PHARMA has confirmed its agreement to the continuation of this process (limited to 15% of daily
share movements)
About Medesis Pharma
To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary AonysO technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood—brain barrier (BBB).
This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer's disease, Huntington's disease, and resistant cancers.
Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated after a civil or military nuclear accident.
French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 12 patent families and 72 patents, resulting from 17 years of research 
Medesis Pharma shares are listed on Euronext Growth Paris: FR001844464 - ALMDP
For more information:
www.medesispharma.com
MEDESIS PHARMA
Jean-Claude Maurel Tél 
+33 4 67 03 03 96 contact@medesispharma.com
CALYPTUS
Marie Calleux Tél +33 1 53 65 68 66 medesispharma@calyptus.net